Bonk, Inc. (NASDAQ:BNKK – Get Free Report) Director Mitchell Austin Rudy purchased 7,500 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of $1.56 per share, with a total value of $11,700.00. Following the completion of the purchase, the director directly owned 73,341 shares in the company, valued at $114,411.96. The trade was a 11.39% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Mitchell Austin Rudy also recently made the following trade(s):
- On Tuesday, June 16th, Mitchell Austin Rudy acquired 2,500 shares of Bonk stock. The shares were purchased at an average price of $1.32 per share, for a total transaction of $3,300.00.
- On Wednesday, June 10th, Mitchell Austin Rudy purchased 12,000 shares of Bonk stock. The shares were purchased at an average cost of $1.37 per share, for a total transaction of $16,440.00.
- On Thursday, April 9th, Mitchell Austin Rudy acquired 31,055 shares of Bonk stock. The stock was purchased at an average cost of $2.82 per share, with a total value of $87,575.10.
Bonk Stock Performance
NASDAQ BNKK remained flat at $1.54 during trading hours on Tuesday. 156,650 shares of the company were exchanged, compared to its average volume of 898,779. The firm has a market capitalization of $12.32 million, a PE ratio of -0.33 and a beta of 1.86. The company’s 50 day simple moving average is $2.13 and its two-hundred day simple moving average is $3.06. Bonk, Inc. has a 1-year low of $1.25 and a 1-year high of $46.90.
Hedge Funds Weigh In On Bonk
Several institutional investors have recently added to or reduced their stakes in BNKK. Geode Capital Management LLC bought a new stake in shares of Bonk in the 4th quarter valued at $128,000. Jane Street Group LLC acquired a new stake in Bonk in the fourth quarter worth $96,000. Steward Partners Investment Advisory LLC acquired a new stake in Bonk in the fourth quarter worth $37,000. Finally, State Street Corp bought a new stake in Bonk in the fourth quarter valued at $33,000. 12.55% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Bonk from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings cut shares of Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.
Check Out Our Latest Stock Report on Bonk
Bonk Company Profile
Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.
Featured Stories
- Five stocks we like better than Bonk
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Bonk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bonk and related companies with MarketBeat.com's FREE daily email newsletter.
